Reading PACB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PACB free→Reading PACB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PACB free→QuarterlyIQ Insights · PACB
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(8.4) + peer(0.2*-1.1) + term(0.0) → 2.71% (capped ±15.0)
in 50 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pacific Biosciences of California, Inc. By: /s/ Jim R. Gibson Jim R. Gibson Chief Financial Officer Date: May 7, 2026
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 12, 2026, Pacific Biosciences of California, Inc. (the “Company”) announced its financial results for its fourth fiscal quarter and year ended December 31, 2025. A copy of the press release containing the announcement is attached as Exhibit 99.1 hereto and is incorporated herein by reference. This information, as well as Exhibit 99.1, is intended to be furnished under
of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Because the Company’s financial statements as of and for the quarter and year ended December 31, 2025 have not yet been finalized or audite…
. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pacific Biosciences of California, Inc. By: /s/ Michele Farmer Michele Farmer Vice President and Chief Accounting Officer Date: November 5, 2025
. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pacific Biosciences of California, Inc. By: /s/ Michele Farmer Michele Farmer Vice President and Chief Accounting Officer Date: August 7, 2025
. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pacific Biosciences of California, Inc. By: /s/ Michele Farmer Michele Farmer Vice President and Chief Accounting Officer Date: May 8, 2025
of this Current Report on Form 8-K, and the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Because the Company’s financial statements as of and for the quarter ended March 31, 20…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 13, 2025, Pacific Biosciences of California, Inc. (the “Company”) announced its financial results for its fourth fiscal quarter and year ended December 31, 2024. A copy of the press release containing the announcement is attached as Exhibit 99.1 hereto and is incorporated herein by reference. This information, as well as Exhibit 99.1, is intended to be furnished under
of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Because the Company’s financial statements as of and for the quarter and year ended December 31, 2024 have not yet been finalized or audite…